Medical devices, healthcare technology and the business of care
COMPANY INTELLIGENCE

Womed Sas

Explore this company’s associated devices, FDA decisions and regulatory history.

Clinical monitoring equipment, editorial photography

Womed Sas

Regulatory records
4
Linked recall entries
0
Headquarters
Not reported
Brand website
Not reported
COMPANY INTELLIGENCE

What the linked records show

MedtechLedger currently links 4 FDA records to the applicant name Womed Sas. It includes 1 original PMA approval. 2 entries are PMA supplements. 1 entry is a 30-day notice. These are records held by this publication, rather than a count of the company’s entire portfolio.

The dated entries run from Sep 9, 2025 to Oct 25, 2026. Individual filings may concern different products or changes to an existing application; review the identifier and decision scope on each record.

Product code MCN appears in 4 of the 4 linked filings. The collection spans 1 FDA product code and 1 original PMA application family. These figures describe the filings available here; they do not establish the company’s total device sales or market share.

The largest PMA family in this collection is P240015, with 4 linked entries. Follow the parent application and its dated supplements to distinguish the original device scope from later changes. 1 linked filing has a current plain-language explanation checked against the recorded FDA decision.

Applicant mailing address recorded by FDA: Batiment Balard Cit, 1919 Rte. De Mende, Montpellier, 34090. Recorded on P240015/S003, decision dated Oct 25, 2026.

Changes described in PMA records

P240015/S003: Womed Leaf

The FDA database entry for P240015/S003, dated 2026-10-25, records an approval of a real-time process supplement from Womed Sas. Supplement type is listed as Real-Time Process, and the supplement reason field cites labeling change covering indications, instructions, shelf life, or tradename. The source statement describes the action as being for labeling changes to reduce the chance of product expulsion. The device sits in the absorbable adhesion barrier category, obstetrics/gynecology specialty, product code MCN, titled Womed Leaf.

The supplement number establishes a link to parent PMA P240015, but this record covers only the supplement, not a fresh approval of the whole system. The stated purpose of reducing expulsion risk is the applicant's or reviewer's reported aim for the labeling change, not independent proof of safety or clinical effectiveness. The entry does not specify which labeling element changed, the prior wording, test data, or the mechanism by which expulsion risk would be reduced; those details are absent from the supplied fields.

FDA approval-order wording

for labeling changes to reduce the chance of product expulsion

Oct 25, 2026 · Real-Time Process

P240015/S002: Womed Leaf

FDA’s recorded scope: approval for changes to the manufacturing process and materials used to manufacture the plunger component of the inserter

Aug 31, 2026 · Real-Time Process

P240015/S001: Womed Leaf

FDA’s recorded scope: to add surface treatment and outsource the bonding process of the outer handle of the inserter and move to a semi-automated process for cutting and assembly

Jan 28, 2026 · 30-Day Notice

P240015: Womed Leaf Resorbable Adhesion Barrier

FDA’s recorded scope: Approval for the Womed Leaf Resorbable Adhesion Barrier is intended to reduce the reoccurrence and severity of post-surgical adhesion formation inside the uterus. It is indicated for adult women undergoing hysteroscopic surgery for symptomatic moderate to severe intrauterine adhesions.

Sep 9, 2025

Subsidiaries and similarly named applicants can have separate records. The links below preserve the applicant and submission identifiers. Source records are linked on each filing.

Regulatory record history

Product / regulatory recordCompanyPathwayDecision dateSource
Womed LeafP240015/S003
Womed SasPMA supplementOct 25, 2026FDA
Womed LeafP240015/S002
Womed SasPMA supplementAug 31, 2026FDA
Womed LeafP240015/S001
Womed SasPMA supplementJan 28, 2026FDA
Womed SasPMA approvalSep 9, 2025FDA
Source information

Source updated Nov 9, 2026. Retrieved Nov 21, 2026.